Mark Dransfield
Critical Care Medicine · Birmingham, ALNPI 1770526725
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $107,142 of the $160,092 with a category attached, or 66.9%. GSK accounts for 62.4% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2019 at $92,490 and has fallen 99.9% since, to $134 in 2025. Among critical care medicine clinicians in AL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 83 payments — averaging $1928.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$100K
- Teva Pharmaceuticals USA, Inc.$18K
- Astrazeneca AB$15K
- Astrazeneca UK Limited$14K
- AstraZeneca$5K
- Genentech, Inc.$4K
- plus $4K from 4 others
Across 83 payments — averaging $4073.44 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$153K
- Pulmonx Corporation$108K
- Boehringer Ingelheim$54K
- GSK$10K
- Pneumrx, Inc$6K
- Novartis$3K
- plus $2K from 2 others
What the payments were for
- Consulting fees$107,14267%
- Travel & lodging$50,05531%
- Food & beverage$1,7491%
- Education$1,1451%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 40 | $99,932 |
| Teva Pharmaceuticals USA, Inc. | 3 | $17,985 |
| Astrazeneca AB | 22 | $15,134 |
| Astrazeneca UK Limited | 3 | $13,725 |
| AstraZeneca | 4 | $5,124 |
| Genentech, Inc. | 3 | $3,951 |
| Pulmonx Corporation | 5 | $1,915 |
| Novartis | 1 | $1,862 |
| F. Hoffmann-la Roche AG | 1 | $330 |
| Verona Pharma, Inc. | 1 | $134 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BEVESPI AEROSPHERE$20,169
- TRELEGY ELLIPTA$13,650
- AirDuo Digihaler$13,625
- ANORO$5,866
- Pulmonx Endobronchial Valve EBV$1,145
- CHARTIS CATHETER$600
- ZEPHYR ENDOBRONCHIAL VALVE$600
- ZEPHYR DELIVERY CATHETER$600
- PULMONX CHARTIS TABLET CONSOLE$600
- Ohtuvayre$134
How this compares
$160,092 in reported general payments places this provider in the 95th percentile of 73 critical care medicine providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 62 | $61,786 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 17 | $13,068 |
| Spiriva HandihalerTiotropium Bromide | 16 | $12,182 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 21 | $11,638 |
| Breo ElliptaFluticasone/Vilanterol | 20 | $7,929 |
| Incruse ElliptaUmeclidinium Bromide | 12 | $5,899 |
| Wixela InhubFluticasone Propion/Salmeterol | 15 | $5,126 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 82 | $3,517 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 11 | $2,774 |
| Roflumilast | 13 | $1,091 |
| Azithromycin | 37 | $932 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 11 | $438 |
| Prednisone | 31 | $107 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta | $99,932 | $87,253115 claims |
| AstraZenecaBreztri Aerosphere | $5,124 | $13,06817 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 73 critical care medicine providers in Alabama.
Other critical care medicine in Birmingham
- James WellsBirmingham$223K
- George SolomonBirmingham$113K
- Tracy LuckhardtBirmingham$28K
- Keith WilleBirmingham$9K
- Victor ThannickalBirmingham$8K
- Vipul ShahBirmingham$6K
- Samuel McElweeBirmingham$5K
- Nicole SchreinerBirmingham$4K
- David LafonBirmingham$4K
- Dhaval RavalBirmingham$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.